- Home
- AVTX vs GLSI Comparison
AVTX vs GLSI Comparison
Compare AVTX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- GLSI
- Stock Information
- Founded
- AVTX 2011
- GLSI 2006
- Country
- AVTX United States
- GLSI United States
- Employees
- AVTX N/A
- GLSI N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- GLSI Health Care
- Exchange
- AVTX Nasdaq
- GLSI Nasdaq
- Market Cap
- AVTX 118.6M
- GLSI 134.6M
- IPO Year
- AVTX 2015
- GLSI 2020
- Fundamental
- Price
- AVTX $9.88
- GLSI $12.18
- Analyst Decision
- AVTX Strong Buy
- GLSI Strong Buy
- Analyst Count
- AVTX 8
- GLSI 1
- Target Price
- AVTX $31.00
- GLSI $39.00
- AVG Volume (30 Days)
- AVTX 335.9K
- GLSI 43.7K
- Earning Date
- AVTX 08-07-2025
- GLSI 08-14-2025
- Dividend Yield
- AVTX N/A
- GLSI N/A
- EPS Growth
- AVTX N/A
- GLSI N/A
- EPS
- AVTX N/A
- GLSI N/A
- Revenue
- AVTX $441,000.00
- GLSI N/A
- Revenue This Year
- AVTX N/A
- GLSI N/A
- Revenue Next Year
- AVTX N/A
- GLSI N/A
- P/E Ratio
- AVTX N/A
- GLSI N/A
- Revenue Growth
- AVTX N/A
- GLSI N/A
- 52 Week Low
- AVTX $3.39
- GLSI $8.06
- 52 Week High
- AVTX $16.00
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- AVTX 76.24
- GLSI 56.92
- Support Level
- AVTX $8.41
- GLSI $11.41
- Resistance Level
- AVTX $9.80
- GLSI $12.35
- Average True Range (ATR)
- AVTX 0.85
- GLSI 0.67
- MACD
- AVTX -0.01
- GLSI -0.06
- Stochastic Oscillator
- AVTX 87.52
- GLSI 52.20
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.